Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma

NCT06029309 is registered in ClinicalTrials.gov with Alvaro Alencar, MD as lead sponsor.

NCT NCT06029309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06029309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
Lead sponsor
Alvaro Alencar, MD
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 3, 2024
Completion date
May 1, 2032
Enrollment
27 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma